Double Bond Between Ring Members Of The Hetero Ring Patents (Class 549/479)
  • Patent number: 9944825
    Abstract: The disclosure relates to curable polysilyl phosphate compounds and compositions as well as related methods and flame-retardant textiles incorporating the same. Curable polysilyl phosphate compounds according to the disclosure include a hydrocarbon moiety comprising at least one phosphate group and more than two hydrolysable silyl groups linked to the hydrocarbon moiety. In some embodiments, the hydrocarbon moiety is derived from spirocyclic pentaerythritol diphosphoryl chloride. The curable polysilyl phosphate compound can applied to a textile substrate and then cured to provide a flame-retardant textile with the cured polysilyl phosphate compound as a coating bonded to the textile substrate.
    Type: Grant
    Filed: January 29, 2014
    Date of Patent: April 17, 2018
    Assignee: EASTERN MICHIGAN UNIVERSITY
    Inventors: Subhas Ghosh, Vijaykumar M. Mannari, Vikas P. Joshi
  • Publication number: 20150105460
    Abstract: Provided in the present invention are various labdane diterpenoid compounds and derivatives thereof for use in preparation of a pharmaceutical composition for preventing or treating neurodegenerative diseases. Also provided in the present invention is a semen biotae extract comprising one or more labdane diterpenoid compounds and derivatives thereof for use in preparation of a pharmaceutical composition for preventing or treating neurodegenerative diseases.
    Type: Application
    Filed: June 4, 2012
    Publication date: April 16, 2015
    Inventors: Weiwei Su, Yonggang Wang, Fengyin Liang, Ning Wang, Zhong Pei, Haibin Liu
  • Patent number: 8987326
    Abstract: The disclosed subject matter provides N-substituted hydroxylamine derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the disclosed subject matter provides methods of using such compounds or pharmaceutical compositions for treating heart failure.
    Type: Grant
    Filed: January 17, 2014
    Date of Patent: March 24, 2015
    Assignee: Cardioxyl Pharmaceuticals, Inc.
    Inventors: Vincent Jacob Kalish, Frederick Arthur Brookfield, Stephen Martin Courtney, Lisa Marie Frost, John P. Toscano
  • Publication number: 20150051403
    Abstract: Disclosed is use of andrographolide derivative as shown by general formula 1 in manufacture of medicaments for anti-hepatitis C virus, and preventing and treating immunological liver damage caused by virus infection and different chemical liver damage.
    Type: Application
    Filed: February 5, 2013
    Publication date: February 19, 2015
    Applicant: ZHENGZHOU UNIVERSITY
    Inventors: Guifu Dai, Songlin Zhu, Yanan Wang, Jian Wu, Dan Zhao, Di Wu, Huanfei Liu, Haiwei Xu, Mengjiao Liu, Jing Zhao, Wei Han, Zhenwei Wu, Hang Wang, Hongmin Liu
  • Publication number: 20150025069
    Abstract: This invention is directed to analogs of 5-(tetradecyloxy)-2-furancarboxylic acid (TOFA) and their use in the treatment of dermatological disorders or conditions characterized by sebaceous gland hyperactivity, such as acne and oily skin, and other dermatological disorders and conditions. This invention is also directed to pharmaceutical compositions comprising analogs of TOFA and a pharmaceutically acceptable excipient for dermatological or oral administration.
    Type: Application
    Filed: October 3, 2014
    Publication date: January 22, 2015
    Inventors: Timothy Scott Daynard, Geoffrey C. Winters, David W.C. Hunt
  • Publication number: 20150025068
    Abstract: A compound of formula (I), useful for the treatment of cancer, inflammation and inflammatory disorders, and a pharmaceutical composition containing the compound.
    Type: Application
    Filed: December 21, 2012
    Publication date: January 22, 2015
    Inventors: Jessica Martinsson, Katarina Faernegardh, Mattias Joensson, Rune Ringom
  • Publication number: 20150010643
    Abstract: This invention relates to a method of treating B cell malignancies, which involves administering to a subject a compound having a structure of formula (I) to cause cell death of a B cell malignancy, thereby treating the B cell malignancy in the subject. Also disclosed are a method of causing cell death of malignant B cells, pharmaceutical compositions and therapeutic systems comprising a compound having a structure of formula (I), and a compound having a structure of formula (I).
    Type: Application
    Filed: February 15, 2013
    Publication date: January 8, 2015
    Applicant: UNIVERSITY OF ROCHESTER
    Inventor: Jiyong Zhao
  • Publication number: 20140350271
    Abstract: The present invention relates to a process for chemical conversion of cellulose isolated from aromatic spent biomass to hydroxymethyl furfural using an eco-friendly and economical liquids system with recoverable and reusable solid Indion catalysts and zeolite-phosphomolybdic acid hybrid catalysts. The present invention further relates to the preparation of an effective hybrid catalyst i.e. zeolite-phosphomolybdic acid catalyst for synthesis of HMF. The selectivity and yield of HMF is nearly doubled in zeolite-phosphomolybdic acid hybrid catalyst compared to the individual catalysts (zeolite or phosphomolybdic acid) or combination of catalysts viz. zeolite and phosphomolybdic acid.
    Type: Application
    Filed: October 3, 2012
    Publication date: November 27, 2014
    Inventors: Prasanta Kumar Rout, Ashween Deepak Nannaware, Ram Rajasekharan
  • Patent number: 8884034
    Abstract: This invention is directed to analogs of 5-(tetradecyloxy)-2-furancarboxylic acid (TOFA) and their use in the treatment of dermatological disorders or conditions characterized by sebaceous gland hyperactivity, such as acne and oily skin, and other dermatological disorders and conditions. This invention is also directed to pharmaceutical compositions comprising analogs of TOFA and a pharmaceutically acceptable excipient for dermatological or oral administration.
    Type: Grant
    Filed: July 1, 2010
    Date of Patent: November 11, 2014
    Assignee: Dermira (Canada), Inc.
    Inventors: Timothy Scott Daynard, Geoffrey C. Winters, David W. C. Hunt
  • Publication number: 20140303377
    Abstract: An object of the present invention is to provide insecticides having high effectiveness.
    Type: Application
    Filed: June 24, 2014
    Publication date: October 9, 2014
    Inventors: Kei Yoshida, Takeo Wakita, Hiroyuki Katsuta, Akiyoshi Kai, Yutaka Chiba, Kiyoshi Takahashi, Hiroko Kato, Nobuyuki Kawahara, Michikazu Nomura, Hidenori Daido, Junji Maki, Shinichi Banba, Atsuko Kawahara
  • Patent number: 8841467
    Abstract: The present invention relates to a novel process for the preparation of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-ol of formula I by reacting a compound of formula VII with the compound of formula R2-OH in the presence of haloginating agent to obtain a compound of formula VI and treating a compound of formula VI with dehaloginating agent to obtain a compound of formula V by reducing a compound of formula V, followed by cylization to obtain compound of formula IV and separating the enantiomer and diastereomers from compound of formula IV to yield a compound of formula I. Compound of formula I is useful as an intermediate in the preparation of protease inhibitors, in particular broad spectrum HIV protease inhibitors, the present invention also relates to process for the preparation of Darunavir from (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-ol.
    Type: Grant
    Filed: July 14, 2011
    Date of Patent: September 23, 2014
    Assignee: Mylan Laboratories Limited
    Inventors: Siva Rama Prasad Vellenki, Arabinda Sahu, Nitin Ashok Shimpi, Anil Ponnuru, Satish Babu Kothari
  • Patent number: 8835467
    Abstract: Compounds are disclosed which inhibit SIR2 base exchange more than deacetylation, thus enhancing SIR2 deacetylation activity. Methods of using the compounds for enhancing SIR2 deacetylation activity and increasing longevity of an organism are also disclosed. Methods for screening for compounds that enhance SIR2 deacetylation activity and increase longevity of an organism are additionally disclosed.
    Type: Grant
    Filed: January 23, 2013
    Date of Patent: September 16, 2014
    Assignee: Albert Einstein College of Medicine of Yeshiva University
    Inventors: Vern L. Schramm, Anthony A. Sauve
  • Publication number: 20140228219
    Abstract: The present invention provides a compound having an excellent efficacy for controlling weeds. A cyclohexanone compound of the formula (I): wherein m is an integer of 1, 2 or 3; n is an integer of any one of 1 to 5; X represents CH2, O, S, S(O) or S(O)2; R1 represents a hydrogen atom or a methyl group; R2 and R3 represents a hydrogen atom, a C1-6 alkyl group and the like; R4 represents a C6-10 aryl group or a five- to six-membered heteroaryl group; G represents a hydrogen atom and the like; Z represents a halogen atom, a cyano group, a nitro group, a phenyl group, a C1-6 alkyl group and the like; is useful as an active ingredient for herbicides.
    Type: Application
    Filed: May 29, 2012
    Publication date: August 14, 2014
    Inventors: Yosuke Nakashima, Yoshinobu Jin, Masato Konobe
  • Publication number: 20140206769
    Abstract: The disclosed subject matter provides N-substituted hydroxylamine derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the disclosed subject matter provides methods of using such compounds or pharmaceutical compositions for treating heart failure.
    Type: Application
    Filed: January 17, 2014
    Publication date: July 24, 2014
    Applicant: CARDIOXYL PHARMACEUTICALS, INC.
    Inventors: Vincent Jacob Kalish, Frederick Arthur Brookfield, Stephen Martin Courtney, Lisa Marie Frost
  • Publication number: 20140051872
    Abstract: The present invention provides catalysts, methods, and reactor systems for converting oxygenated hydrocarbons to oxygenated compounds. The invention includes methods for producing cyclic ethers, monooxygenates, dioxygenates, ketones, aldehydes, carboxylic acids, and alcohols from oxygenated hydrocarbons, such as carbohydrates, sugars, sugar alcohols, sugar degradation products, and the like, using catalysts containing palladium, molybdenum, tin, and tungsten. The oxygenated compounds produced are useful in the production of liquid fuels, chemicals, and other products.
    Type: Application
    Filed: August 15, 2012
    Publication date: February 20, 2014
    Applicant: Virent, Inc.
    Inventors: Brian Blank, Randy Cortright, Taylor Beck, Elizabeth Woods, Mike Jehring
  • Publication number: 20130324708
    Abstract: A carbohydrate-containing feedstock is converted in a process by contacting the feedstock in a first step with an alcohol in the presence of a first acid catalyst at a temperature below 100° C. to yield an intermediate product, and contacting at least part of the intermediate product in a second step with an alcohol in the presence of a second acid catalyst at a temperature of at least 100° C. Products of such conversion may include hydroxymethylfurfural, hydroxymethylfurfural ethers, levulinic acid, esters thereof and furfural.
    Type: Application
    Filed: December 28, 2011
    Publication date: December 5, 2013
    Applicant: FURANIX TECHNOLOGIES B.V.
    Inventors: Ana Sofia Vagueiro de Sousa Dias, Gerardus Johannes Maria Gruter, Robert-Jan van Putten
  • Publication number: 20130303466
    Abstract: Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administering a composition comprising a chemosensory receptor ligand. Also provided herein are chemosensory receptor ligand compositions and methods for the preparation thereof for use in the methods of the present invention.
    Type: Application
    Filed: October 18, 2011
    Publication date: November 14, 2013
    Applicant: ELCELYX THERAPEUTICS, INC.
    Inventors: Martin R. Brown, Christopher R.G. Jones, Nigel R.A. Beeley, Alain D. Baron
  • Publication number: 20130274487
    Abstract: The present invention relates to the field of catalytic hydrogenation and, more particularly, to the use of specific ruthenium catalysts, or pre-catalysts, in hydrogenation processes for the reduction of ketones and/or aldehydes into the corresponding alcohol respectively. Said catalysts are ruthenium complexes comprising a tetradentate ligand (L4) coordinating the ruthenium with: two nitrogen atoms, each in the form of a primary or secondary amine (i.e. a NH2 or NH group) or N-alkyl imine functional groups (i.e. a C?N group), and two sulfur atoms, each in the form of thioether functional groups.
    Type: Application
    Filed: December 19, 2011
    Publication date: October 17, 2013
    Applicant: FIRMENICH SA
    Inventors: Sylvia Joyeuse Adélaïde Ada Saudan, Michel Alfred Joseph Saudan
  • Patent number: 8530680
    Abstract: A method for inhibiting the growth of a microorganism using an effective amount of one or more of the following synthetic brominated furanones: (i) 4-bromo-5Z-(bromomethylene)-3-methylfuran-2-one; (ii) 3-(dibromomethyl)-5-(dibromomethylene)furan-2-one; (iii) 3-(bromomethyl)-5-(dibromomethylene)furan-2-one; (iv) 4-bromo-3-(bromomethyl)-5Z-(bromomethylene)furan-2-one; or (v) 4-bromo-5-(dibromomethyl)-3-methylfuran-2(5H)-one. The brominated furanones inhibit the growth of both fungi and bacteria, including the fungal species Candida albicans, Gloeophyllum trabeum, Chaetomium globosum, and Trametes versicolor and the bacterial species Pseudomonas aeruginosa. The brominated furanones can be used topically or internally to treat human infections, and can be used to treat other objects, such as wood building supplies, to prevent fungal rot.
    Type: Grant
    Filed: June 21, 2012
    Date of Patent: September 10, 2013
    Assignee: Syracuse University
    Inventors: Dacheng Ren, Yan Yeung Luk
  • Publication number: 20130225619
    Abstract: The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are substituted heterocyclic amine derivative compound and pharmaceutical compositions comprising these compounds. The subject compositions are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease.
    Type: Application
    Filed: January 18, 2013
    Publication date: August 29, 2013
    Applicant: Acucela Inc.
    Inventors: Vladimir A. Kuksa, Mark W. Orme, Feng Hong, Ryo Kubota
  • Patent number: 8519166
    Abstract: A method for inhibiting the growth of a microorganism using an effective amount of one or more of the following synthetic brominated furanones: (i) 4-bromo-5Z-(bromomethylene)-3-methylfuran-2-one; (ii) 3-(dibromomethyl)-5-(dibromomethylene)furan-2-one; (iii) 3-(bromomethyl)-5-(dibromomethylene)furan-2-one; (iv) 4-bromo-3-(bromomethyl)-5Z-(bromomethylene)furan-2-one; or (v) 4-bromo-5-(dibromomethyl)-3-methylfuran-2(5H)-one. The brominated furanones inhibit the growth of both fungi and bacteria, including the fungal species Candida albicans, Gloeophyllum trabeum, Chaetomium globosum, and Trametes versicolor and the bacterial species Pseudomonas aeruginosa. The brominated furanones can be used topically or internally to treat human infections, and can be used to treat other objects, such as wood building supplies, to prevent fungal rot.
    Type: Grant
    Filed: November 13, 2009
    Date of Patent: August 27, 2013
    Assignee: Syracuse University
    Inventors: Dacheng Ren, Yan Yeung Luk
  • Publication number: 20130053416
    Abstract: 3-Heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals The present invention relates to compounds of the formula I, wherein Ht, G, R10, R30, R40, R50 and R60 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.
    Type: Application
    Filed: July 26, 2012
    Publication date: February 28, 2013
    Applicant: SANOFI
    Inventors: Sven RUF, Josef PERNERSTORFER, Thorsten SADOWSKI, Georg HORSTICK, Herman SCHREUDER, Christian BUNING, Klaus WIRTH
  • Patent number: 8383653
    Abstract: Compounds are disclosed which inhibit SIR2 base exchange more than deacetylation, thus enhancing SIR2 deacetylation activity. Methods of using the compounds for enhancing SIR2 deacetylation activity and increasing longevity of an organism are also disclosed. Methods for screening for compounds that enhance SIR2 deacetylation activity and increase longevity of an organism are additionally disclosed.
    Type: Grant
    Filed: June 30, 2004
    Date of Patent: February 26, 2013
    Assignee: Albert Einstein College of Medicine of Yeshiva University
    Inventors: Vern L. Schramm, Anthony A. Sauve
  • Publication number: 20120330038
    Abstract: A novel bis-phosphate compound is provided which can be applied to a wide range of reactive substrates and reactions as an asymmetric reaction catalyst and can realize an asymmetric reaction affording a high yield and a high enantiomeric excess. The bis-phosphate compound has a tetraaryl skeleton represented by General Formula (1). In an asymmetric reaction, an amidodiene and an unsaturated aldehyde compound are reacted with each other in the presence of the optically active bis-phosphate compound to give an optically active amidoaldehyde. The invention allows a reaction such as an asymmetric Diels-Alder reaction to proceed efficiently, which has been difficult with conventional mono-phosphate compounds.
    Type: Application
    Filed: March 8, 2011
    Publication date: December 27, 2012
    Applicants: API Corporation, National University Corporation TOHOKU UNIVERSITY
    Inventors: Masahiro Terada, Norie Momiyama, Tohru Konno
  • Publication number: 20120322995
    Abstract: The invention provides a process for producing a ?-dihydrofuran derivative represented by formula (1) or a ?-tetrahydrofuran derivative represented by formula (4), characterized in that the process includes causing a dialkyl dicarbonate, a diaralkyl dicarbonate, or a halide to act on a diol compound represented by formula (2) or (3). The invention also provides a process for producing 4?-ethynyl-2?,3?-didehydro-3?-deoxythymidine or an analog thereof, the process including glycosylation and deprotection.
    Type: Application
    Filed: February 7, 2011
    Publication date: December 20, 2012
    Inventors: Yusuke Iriyama, Tsutomu Higashiyama
  • Patent number: 8314260
    Abstract: Accordingly, the current invention provides a method for the manufacture of an ether or ester of 5-hydroxymethyl-furfural by reacting a hexose-containing starting material or HMF with an alcohol or an organic acid dissolved into an ionic liquid, using a metal chloride as catalyst.
    Type: Grant
    Filed: September 5, 2008
    Date of Patent: November 20, 2012
    Assignee: Furanix Technologies B.V.
    Inventors: Gerardus Johannes Maria Gruter, Leo Ernest Manzer, Ana Sofia Vagueiro De Sousa Dias, Frits Dautzenberg, Jindra Purmova
  • Publication number: 20120208807
    Abstract: This invention is directed to analogs of 5-(tetradecyloxy)-2-furancarboxylic acid (TOFA) and their use in the treatment of dermatological disorders or conditions characterized by sebaceous gland hyperactivity, such as acne and oily skin, and other dermatological disorders and conditions. This invention is also directed to pharmaceutical compositions comprising analogs of TOFA and a pharmaceutically acceptable excipient for dermatological or oral administration.
    Type: Application
    Filed: July 1, 2010
    Publication date: August 16, 2012
    Applicant: VALOCOR THERAPEUTICS, INC.
    Inventors: Timothy Scott Daynard, Geoffrey C. Winters, David W.C. Hunt
  • Patent number: 8198468
    Abstract: A salt of a carboxylic acid with an aminoketone of formula II.
    Type: Grant
    Filed: March 8, 2011
    Date of Patent: June 12, 2012
    Assignee: Lonza AG
    Inventors: Dominique Michel, Hanspeter Mettler, John McGarrity
  • Patent number: 8193380
    Abstract: A salt of a carboxylic acid with an aminoalcohol of formula I.
    Type: Grant
    Filed: March 8, 2011
    Date of Patent: June 5, 2012
    Assignee: Lonza AG
    Inventors: Dominique Michel, Hanspeter Mettler, John McGarrity
  • Patent number: 8188303
    Abstract: The present invention provides an antimalarial compound 3-[2-(2-Hydroxymethyl-1,4a,5-trimethyl-7-oxo-1,2,3,4,4a,7 8,8a-octahydronaphthalen-1-yl)-ethyl]-5H-furan-2-one of the formula 1 given below or pharmaceutically acceptable derivatives thereof, isolated from Gomphostema niveum and also provides a method for the extraction thereof as well as methods for the treatment of malaria using said compound.
    Type: Grant
    Filed: August 30, 2006
    Date of Patent: May 29, 2012
    Assignee: The Director General, Defence Research and Development Organisation
    Inventors: Mahabir Prashad Kaushik, Duraipandian Thavaselvam, Manisha Nivsarkar, Badri Narayan Acharya, Subramaniam Prasanna, Krishnamurthy Sekhar
  • Patent number: 8124796
    Abstract: Disclosed is a method of preparing 3-hydroxytetrahydrofuran using cyclodehydration. More particularly, this invention relates to a method of preparing 3-hydroxytetrahydrofuran, including subjecting 1,2,4-butanetriol to cyclodehydration under reaction conditions of a reaction temperature of 30˜180° C. and reaction pressure of 5000 psig or less in the presence of a strong acid cation exchange resin catalyst having a sulfonic acid group as an exchange group. According to the method of this invention, 3-hydroxytetrahydrofuran can be economically prepared at higher yield and productivity than when using conventional methods.
    Type: Grant
    Filed: January 10, 2006
    Date of Patent: February 28, 2012
    Assignee: SK Biopharmaceuticals Co., Ltd.
    Inventors: Byong Sung Kwak, Tae Yun Kim, Jin Woong Kim, Sang Il Lee, Ki Ho Koh
  • Patent number: 8124649
    Abstract: The invention provides compounds that inhibit PIM kinases and Flt3 kinase, and compositions containing such compounds. These compounds and compositions are useful for treating proliferative disorders such as cancer, as well as other kinase-associated conditions including inflammation.
    Type: Grant
    Filed: June 30, 2009
    Date of Patent: February 28, 2012
    Assignee: Cylene Pharmaceuticals, Inc.
    Inventors: Mustapha Haddach, Johnny Yasuo Nagasawa
  • Patent number: 8105504
    Abstract: Organic materials which possess outstanding stability to oxidative, thermal or light-induced degradation comprise as stabilizers at least one compound of the formula (I) wherein the general symbols are as defined in claim 1. The compounds of formula I are especially useful as stabilizers for protecting polymers and lubricants against oxidative, thermal or light-induced degradation and as scavengers for oxidized developer in color photographic material.
    Type: Grant
    Filed: August 22, 2005
    Date of Patent: January 31, 2012
    Assignee: BASF SE
    Inventors: Michèle Gerster, Peter Nesvadba
  • Publication number: 20120015923
    Abstract: We describe for the first time that andrographolide derivatives such as DDAG effectively reduced OVA-induced inflammatory cell recruitment into BAL fluid, IL-4, IL-5, IL-13 and eotaxin production, serum IgE synthesis, pulmonary eosinophilia, mucus hypersecretion and AHR in a mouse asthma model potentially via inhibition of NF-?B activity. Moreover, low dose of DDAG and glucocorticoid combination treatment synergistically attenuate inflammation in mouse asthma model. These findings support a therapeutic value for DDAG in the treatment of asthma.
    Type: Application
    Filed: March 24, 2010
    Publication date: January 19, 2012
    Applicant: NATIONAL UNIVERSITY OF SINGAPORE
    Inventor: Wai Shiu Fred Wong
  • Publication number: 20110301365
    Abstract: This invention relates to novel alpha-substituted ?,?-unsaturated E- or Z-aldehydes, or isomer mixture thereof, of the formula in which R1 and R2 may be identical or different and are each H or a hydrocarbon, in which the hydrocarbon may have one or more heteroatoms and R3 and R4 may be identical or different and are each a hydrocarbon, in which the hydrocarbon may have one or more heteroatoms, and R5 may be identical or different and is H or a hydrocarbon, in which the hydrocarbon may have one or more heteroatoms, to the use thereof, and to processes for their preparation. The invention further relates to the preparation of further intermediates for pharmaceuticals and to the preparation of the pharmaceuticals.
    Type: Application
    Filed: August 8, 2011
    Publication date: December 8, 2011
    Applicant: DSM IP Assets B.V.
    Inventors: Gerhard STEINBAUER, Martina Kotthaus, Klaus Edegger, Stefaan Marie Andre De Wildeman, Henricus Martinus Maria Gerardus Straatman, Anna Maria Cornelia Francisca Castelijns, Andreas Hendrikus Maria De Vries
  • Publication number: 20110207923
    Abstract: Disclosed are processes for isomerizing saccharides. Also disclosed are processes for converting saccharides to furan derivatives. Also disclosed are processes for converting starch to furan derivatives.
    Type: Application
    Filed: January 14, 2011
    Publication date: August 25, 2011
    Applicant: CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: Manuel Moliner-Marin, Yuriy Roman-Leshkov, Mark E. Davis, Eranda Nikolla
  • Publication number: 20110201616
    Abstract: [Object] A compound which is useful as an EP1 receptor antagonist is provided. [Means for Solution] The present inventors investigated EP1 receptor antagonists, and confirmed that a compound having a sulfonamide structure, in which the nitrogen atom of the sulfonamide structure is substituted with 2-fluoropropyl group, 3-fluoro-2-methylpropyl group or the like, has a potent EP1 receptor antagonistic action, thereby completing the present invention. The sulfonamide compound of the present invention has a potent EP1 receptor antagonistic action and can be used as an agent for preventing and/or treating a lower urinary tract symptom or the like.
    Type: Application
    Filed: June 22, 2009
    Publication date: August 18, 2011
    Applicant: Astellas Pharma Inc.
    Inventors: Hideki Kubota, Issei Tsukamoto, Kazunori Kamijo, Koji Kato, Yuta Fukuda, Hidenori Azami
  • Patent number: 7989013
    Abstract: The invention relates to new derivatives of 2-methyl-3-furanthiol which are useful as flavoring ingredients to confer meaty, juicy taste to a large variety of edible consumer products, chewing gums and oral care products, without imparting thereto undesirable off-notes typical of prior known furanthiol derivatives.
    Type: Grant
    Filed: July 31, 2007
    Date of Patent: August 2, 2011
    Assignee: Firmenich SA
    Inventors: Alain Chaintreau, Christian Starkenmann, Sabine Rochat, François Benzi
  • Publication number: 20110178108
    Abstract: A group of amino substituted benzoyl derivatives, their preparation and their use. The screening and research on an antiviral drug with hA3G/Vif as a target point proves that the 3-amino benzoyl derivatives not only have the combined activity for the hA3G/Vif, but also have a function of inhibiting replication of viruses. The present invention provides the possible breakthrough progress for the problem of HIV drug resistance, thereby providing a novel clinical antiviral drug which has higher efficiency.
    Type: Application
    Filed: September 28, 2009
    Publication date: July 21, 2011
    Applicant: Institute of Medicinal Biotechnology Academy of Medical Science
    Inventors: Jian-Dong Jiang, Liyan Yu, Shan Cen, Zhourong Li, Yanping Li, Jlan Xu
  • Publication number: 20110178102
    Abstract: Compounds are disclosed which inhibit SIR2 base exchange more than deacetylation, thus enhancing SIR2 deacetylation activity. Methods of using the compounds for enhancing SIR2 deacetylation activity and increasing longevity of an organism are also disclosed. Methods for screening for compounds that enhance SIR2 deacetylation activity and increase longevity of an organism are additionally disclosed.
    Type: Application
    Filed: June 30, 2004
    Publication date: July 21, 2011
    Applicant: ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY
    Inventors: Vern L Schramm, Anthony A. Suave
  • Patent number: 7973182
    Abstract: A process for the preparation of enantiomerically pure 1-substituted-3-amino-alcohols, particularly of (S)-(?)- and (R)-(+)-3-N-methylamino-1-(2-thienyl)-1-propanol, by asymmetrically hydrogenating salts of a carboxylic acids with an aminoketone of the formula: wherein R1 is 2-thienyl, 2-furanyl or phenyl, each optionally substituted with one or more halogen atoms and/or one or more C1-4-alkyl or C1-4-alkoxy groups, and wherein R2 is C1-4-alkyl or phenyl, each optionally substituted with one or more halogen atoms and/or one or more C1-4-alkyl or C1-4-alkoxy groups. The corresponding aminoalcohols are obtained by subsequent hydrolysis of their salts. Salts of a carboxylic acid with the aminoketones and the aminoalcohols obtained by asymmetrically hydrogenating the aminoketones, respectively.
    Type: Grant
    Filed: February 21, 2005
    Date of Patent: July 5, 2011
    Assignee: Lonza Ltd.
    Inventors: Dominique Michel, Hanspeter Mettler, John McGarrity
  • Publication number: 20110123470
    Abstract: The present invention relates to butenolide compounds having cytoprotection such as antioxidant, anti-inflammatory and/or antifungal properties, and which are derived from the marine fungus Aureobasidium.
    Type: Application
    Filed: May 2, 2008
    Publication date: May 26, 2011
    Applicant: Aquapharm Bio-Discovery Ltd.
    Inventors: Liming Yan, Andrew Mearns Spragg, Karen Jukes
  • Publication number: 20110105743
    Abstract: A method is disclosed for synthesizing 2?,3?-didehydro-2?,3?-dideoxynucleosides (d4Ns) from a nucleophile-mediated elimination, such as a telluride-mediated elimination reaction. After substitution of 2,2?-anhydronucleosides with a nucleophile, such as a telluride monoanion, a telluride intermediate is formed, and its elimination leads to formation of the olefin products (d4Ns). This disclosure describes this telluride-assisted (or nucleophile-assisted) reaction and how to facilitate the substitution and elimination in order to form d4Ns.
    Type: Application
    Filed: March 20, 2009
    Publication date: May 5, 2011
    Inventors: Zhen Huang, Jia Sheng
  • Publication number: 20110082202
    Abstract: The invention relates to fatty acid acifran derivatives; compositions comprising an effective amount of a fatty acid acifran derivative; and methods for treating or preventing an metabolic disease comprising the administration of an effective amount of a fatty acid acifran derivative.
    Type: Application
    Filed: October 5, 2010
    Publication date: April 7, 2011
    Inventors: Jill C. Milne, Michael R. Jirousek, Jean E. Bemis, Chi B. Vu
  • Publication number: 20110077406
    Abstract: Embodiments of the invention provide methods and materials for chemical cross-coupling reactions that utilize unconventional phenol derivatives as cross-coupling partners. Embodiments of the invention can be used to synthesize a variety of useful organic compounds, for example the anti-inflammatory drug flurbiprofen.
    Type: Application
    Filed: September 24, 2010
    Publication date: March 31, 2011
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Neil K. Garg, Kyle W. Quasdorf, Xia Tian
  • Publication number: 20110054018
    Abstract: Optimal compositions of derivatives of 5-methyl-3(2H)-furanone compounds and phenylpropanoid polyketides related to inotilone, that exert biological response modification in health and disease, and their method of preparation, are disclosed. Methods of treating degenerative conditions stemming from over-expression of inducible nitric oxide synthase (iNOS) using these compositions are also disclosed.
    Type: Application
    Filed: August 31, 2010
    Publication date: March 3, 2011
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Samuel Manoharan Thomas, Subbalakshmi Prakash
  • Patent number: 7868204
    Abstract: The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.
    Type: Grant
    Filed: March 25, 2005
    Date of Patent: January 11, 2011
    Assignee: MethylGene Inc.
    Inventors: Daniel Delorme, Soon Hyung Woo, Arkadii Vaisburg, Oscar Moradei, Silvana Leit, Stephane Raeppel, Sylvie Frechette, Giliane Bouchain
  • Publication number: 20100322880
    Abstract: The invention relates to compounds of formula (I) wherein R1, R2, R3, R4 have the meaning cited in the claims, to methods for the production thereof, to agents containing said compounds and to their use for the functionalisation of matrices, in particular their use as skin and/or hair-binding UV filters.
    Type: Application
    Filed: January 14, 2009
    Publication date: December 23, 2010
    Inventors: Thomas Rudolph, Philipp Buehle
  • Publication number: 20100299991
    Abstract: The current invention provides a method for the manufacture of an ether of 5-hydroxymethylfurfural by reacting a hexose-containing starting material with an olefin in the presence of an acid catalyst
    Type: Application
    Filed: September 5, 2008
    Publication date: December 2, 2010
    Applicant: FURANIX TECHNOLOGIES B.V.
    Inventor: Gerardus Johannes Maria Gruter
  • Patent number: 7803837
    Abstract: System for selecting a color shade comprising a very small number of color display cards with mixed shades of two or more colors. The system comprises means for selecting one shade among mixed shades, means for presenting the selected mixed shade as well as means for specifying the selected mixed shade for making paint in the desired color tone.
    Type: Grant
    Filed: November 21, 2006
    Date of Patent: September 28, 2010
    Assignee: Arena Pharmaceuticals, Inc.
    Inventors: Jae-Kyu Jung, Graeme Semple, Benjamin R. Johnson